Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Erasca (ERAS)
NASDAQ:ERAS
ERAS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.45 - $3.45
Previous CloseN/A
Volume148.24K
Average Volume (3M)1.40M
Market Cap
$438.23M
Enterprise Value$504.94M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.92
Next Earnings
Mar 20, 2025EPS Estimate
-0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.83
Shares Outstanding282,727,300
10 Day Avg. Volume1,296,998
30 Day Avg. Volume1,401,502
Standard Deviation0.19
R-Squared0.09
Alpha-0.05
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)739.89
Price to Cash Flow (P/CF)-4.80
P/FCF Ratio0.00
Enterprise Value/Market Cap1.15
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-135.30
Enterprise Value/Ebitda-3.34
Forecast
1Y Price Target
$5.00Price Target Upside242.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Erasca News
PremiumCompany Announcements
Erasca Highlights Strategic Focus at Healthcare Conference
PremiumCompany Announcements
Erasca, Inc. Reports Strong Progress in Oncology Pipeline
---
Bulls Say, Bears Say
Bulls Say
Clinical DataUpdated data from SEACRAFT-1’s melanoma cohort demonstrated a 40% response rate and an 80% disease control rate, with early signs of durability being encouraging.
Regulatory ApprovalsThe combination of naporafenib and trametinib has received Fast Track Designation for advanced NRASm melanoma.
Bears Say
Efficacy In Non-Melanoma TumorsEfficacy in non-melanoma tumor types was limited, with a 23% response rate, which was anticipated given the complex MAPK feedback across different tissue types.
---
Ownership Overview
22.57% Insiders
10.56% Mutual Funds
<0.01% Other Institutional Investors
57.13% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ERAS FAQ
What was Erasca’s price range in the past 12 months?
Erasca lowest stock price was $1.45 and its highest was $3.45 in the past 12 months.
What is Erasca’s market cap?
Erasca’s market cap is $438.23M.
When is Erasca’s upcoming earnings report date?
Erasca’s upcoming earnings report date is Mar 20, 2025 which is in 26 days.
How were Erasca’s earnings last quarter?
Erasca released its earnings results on Nov 12, 2024. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.167 by $0.057.
Is Erasca overvalued?
According to Wall Street analysts Erasca’s price is currently Undervalued.
Does Erasca pay dividends?
Erasca does not currently pay dividends.
What is Erasca’s EPS estimate?
Erasca’s EPS estimate is -0.13.
How many shares outstanding does Erasca have?
Erasca has 282,727,300 shares outstanding.
What happened to Erasca’s price movement after its last earnings report?
Erasca reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.167. Following the earnings report the stock price went down -4.682%.
Which hedge fund is a major shareholder of Erasca?
Currently, no hedge funds are holding shares in ERAS
---
Erasca Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (242.47% Upside)
$5.00 (242.47% Upside)
Blogger Sentiment
Bullish
ERAS Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.3%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-24.87%
12-Months-Change
Fundamentals
Return on Equity
-40.33%
Trailing 12-Months
Asset Growth
26.11%
Trailing 12-Months
Company Description
Erasca
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes two clinical-stage programs (ERK and SHP2 inhibitors), two preclinical-stage programs (CNS-penetrant KRAS G12C and EGFR inhibitors), and seven discovery-stage programs targeting other key oncogenic drivers.
---
ERAS Stock 12 Month Forecast
Average Price Target
$5.00
▲(242.47% Upside)
Technical Analysis
Fate Therapeutics
―
Blueprint Medicines
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Best Analysts Covering ERAS
1 Year
1 Year Success Rate
2/7 ratings generated profit
1 Year Average Return
-12.73%
reiterated a buy rating 3 months ago
Copying Andres Y. Maldonado's trades and holding each position for 1 Year would result in 28.57% of your transactions generating a profit, with an average return of -12.73% per trade.
---